Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 265–288 of 297
mPGES-2 Links Kidney Aging to Bone Loss
Podocyte-derived mPGES-2 regulates both renal aging and bone loss in aging, establishing a direct mechanistic link between kidney function decline and skeletal deterioration. This finding identifies a specific molecular pathway that coordinates the decline of two major systems involved in longevity and quality of life.
Dopamine neuron replacement emerges as Parkinson's regenerative therapy
Kenai Therapeutics completed enrollment in its Phase 1b/2a REPLACE trial of RNDP-001, an off-the-shelf cell therapy designed to replace dopamine-producing neurons lost to Parkinson's disease rather than merely compensate for their absence. This approach represents a fundamental shift from symptomatic management toward actual neural regeneration, with potential implications for how neurodegenerative diseases are treated.
Immune Tolerance Induction Unlocks Allogeneic Islet Therapy
LyGenesis received funding to develop immune tolerance protocols for pancreatic islet transplantation in type 1 diabetes, leveraging thymic biology to enable allogeneic cell therapy without chronic immunosuppression. This approach addresses a critical barrier in cellular regenerative medicine: preventing immune rejection while restoring endocrine function.
Neural Regeneration Outpaces Dopamine Replacement in Parkinson's
TreeFrog Therapeutics' TFG-001, a 3D neural microtissue therapy, demonstrated accelerated dopamine release and neural reconnection in preclinical Parkinson's models, suggesting a shift from symptomatic treatment toward regenerative restoration of damaged neural architecture. This approach addresses a fundamental longevity challenge: whether neurodegenerative decline can be reversed through structural repair rather than chemical compensation.
Autophagy‐Independent Function of ATG‐18 Is Essential for Gonadal Longevity in Caenorhabditis elegans
ATG-18, a protein long associated with autophagy, extends lifespan through a mechanism independent of autophagy itself when the germline is removed. In the intestine, ATG-18 extends lifespan by interacting with PCK-2, an enzyme involved in glucose production, revealing a tissue-specific, non-autophagic pathway to longevity.
Youthful blood proteins found in Swiss centenarians
The SWISS100 study reveals that centenarians maintain blood protein profiles resembling those of much younger adults, with notably lower oxidative stress and finely balanced metabolic systems. This molecular signature suggests that exceptional longevity correlates with sustained cellular integrity rather than accelerated compensatory mechanisms, offering a model for understanding how aging can be slowed at the fundamental biological level.
SIRT6 Gene Therapy Improves Survival in Aging Dogs
Genflow's SIRT6-targeted gene therapy in aging dogs showed improved survival at three months post-treatment with no adverse events reported. The trial, enrolling 24 beagles over age 10, represents an early-stage assessment of whether genetic interventions can reverse hallmarks of aging in a mammalian model relevant to human longevity research.
Immune-Evasive Insulin Cells Survive Without Suppression
Sana Biotechnology's immune-evasive cell therapy (UP421) has demonstrated survival of transplanted insulin-producing cells without immunosuppressive medication in a first-in-human study, with transplanted cells responding dynamically to glucose levels after 14 months. This approach fundamentally reframes type 1 diabetes treatment from immune suppression to immune tolerance, with potential implications for regenerative medicine across multiple organ systems.
FDA fast-tracks United Therapeutics’ bioengineered liver tech
United Therapeutics' bioengineered liver system, miroliverELAP, has received FDA Regenerative Medicine Advanced Therapy designation, accelerating its development as a bridge therapy for acute liver failure patients. The technology uses a decellularized pig liver scaffold seeded with human cells to provide extracorporeal organ support, potentially improving survival in the 30% of patients ineligible for or unable to access transplantation in time.
Designs for Health launches NeuroCalm Peptide for gut-brain support
Designs for Health introduced NeuroCalm Peptide, combining a milk-derived peptide (Lactium) with a heat-treated Lactobacillus strain to modulate the gut-brain axis. Clinical evidence suggests the formulation may reduce perceived stress and salivary cortisol while supporting sleep quality and emotional resilience through microbiome and nervous system pathways.
Adjustable Gene Therapy Turns Fat Cells Into Controllable Drug Factories
Remedium Bio has secured $10 million in Series A funding to develop adjustable gene therapies that reprogram fat cells to produce therapeutic proteins long-term. The platform's ability to modulate protein expression after treatment addresses a fundamental limitation of traditional gene therapy: the inability to change dosing once administered.
ULK1 Restores Cellular Cleanup in Alzheimer's Models
Elevated ULK1 expression enhances autophagy and mitophagy pathways, reducing amyloid and tau accumulation while delaying cognitive decline in Alzheimer's models. This positions cellular cleanup mechanisms as a direct target for disease modification rather than symptomatic management.
Cognition Therapeutics reports Zervimesine slows NPI decline in DLB
Zervimesine (CT1812) demonstrated an 86% slowing of neuropsychiatric symptom decline in dementia with Lewy bodies patients compared to placebo in Phase 2 testing. This result supports advancement to late-stage trials and suggests a potential disease-modifying mechanism for a condition with limited therapeutic options.
Multi-tissue transcriptomic aging atlas reveals predictive aging biomarkers in the killifish
Researchers created a multi-tissue transcriptomic atlas across thirteen tissues in African turquoise killifish at six life stages, identifying molecular patterns of aging that vary by tissue type and sex. This resource establishes predictive biomarkers for aging dynamics and demonstrates how systemic and local factors drive age-related changes across the organism.
AI-Designed TNIK Inhibitor Targets Aging in Pulmonary Fibrosis
Insilico Medicine's rentosertib, an AI-designed TNIK inhibitor discovered through aging-biology-informed target identification, has advanced to Phase III trials for idiopathic pulmonary fibrosis. The program demonstrates that computational drug discovery combined with geroscience principles can identify therapeutically relevant targets overlooked by conventional approaches.
Transposon’s $22m ARPA-H award to test aging-fighting drug
Transposon Therapeutics received a $22 million ARPA-H grant to study TPN-101, a drug designed to inhibit LINE-1 retrotransposon activity and slow fundamental aging processes rather than treat individual diseases. The approach targets age-related inflammation driven by DNA elements that become dysregulated with age, potentially extending healthspan across multiple conditions simultaneously.
XPRIZE Healthspan: Functional Recovery Trials Begin
XPRIZE Healthspan has advanced 20 finalists to clinical trials within its $101 million competition, with ten teams receiving $1 million each to test interventions targeting age-related decline in muscle, cognitive, and immune function. The transition from preclinical promise to coordinated human trials represents a critical inflection point: therapeutic mechanisms now must demonstrate measurable functional restoration in adults aged 50–90 within one year.
Aging‐Driven Immunosuppression: The Role of Tregs in the Ovarian Tumor Microenvironment
In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.
20/20 BioLabs expands longevity test with kidney risk tech
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to expand its longevity testing platform beyond inflammation markers into earlier risk detection. The addition addresses a substantial gap: over 35 million Americans have chronic kidney disease, yet most remain unaware until significant progression occurs, making early identification clinically actionable for preventing age-related decline.
Endlyz raises Seed 2 financing, leans into root-cause neuroscience
Endlyz Therapeutics is pursuing disease modification in Parkinson's by targeting lysosomal dysfunction at the cellular level, addressing the root cause of neurodegeneration rather than managing symptoms. This approach represents a shift toward interventions that could slow disease progression before irreversible damage accumulates.
Acorn Biolabs treats first patients in randomized hair regeneration trial
Acorn Biolabs has initiated a randomized, controlled trial of YOU, an autologous secretome derived from hair follicle stem cells, to treat androgenic alopecia. The study will measure changes in hair density, thickness, and patient outcomes against placebo, establishing whether personalized regenerative approaches offer clinically meaningful advantages over existing pharmacologic treatments.
PrimeGen US to merge with DT Cloud Star in $1.5B SPAC deal
PrimeGen US, a regenerative medicine company developing stem cell and exosome therapies, is merging with a SPAC at a $1.5 billion valuation to advance clinical trials for acute liver injury and related conditions. The capital infusion targets acceleration of regulatory pathways and commercialization of cell-based treatments grounded in two decades of proprietary stem cell research.
Genflow reveals early data from SIRT6 gene therapy trial in dogs
Genflow's SIRT6 gene therapy demonstrated superior survival and functional improvements in aged beagles across multiple endpoints, including muscle preservation, frailty reduction, and quality of life measures. This interim data from a proof-of-concept trial establishes preliminary evidence that SIRT6 activation may mitigate age-related functional decline, with potential implications for human therapeutic development.
Role of Succinate Dehydrogenase in Age‐Related Th17 Inflammation
Succinate dehydrogenase (SDH), a mitochondrial enzyme, becomes overactive in aging T cells and drives an age-related shift toward Th17 inflammatory responses. Inhibiting SDH in older adults' T cells reduces proinflammatory cytokine production, while restoring succinate levels in younger T cells reproduces the inflammatory profile seen in aging.